Oncology

Tregzi is indicated in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival.

Findings from EPCORE DLBCL-4 show that fixed-duration epcoritamab plus lenalidomide significantly improved progression-free survival (PFS) versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The blood test offers a promising new approach to identify patients who are at high risk for recurrence and guide precision treatment strategies.

Oncology Pharmacists Connect 2026 emphasized the pharmacist’s role in translating rapidly evolving evidence into patient-centered, operationally feasible cancer care.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

A combination regimen of azacitidine, venetoclax, and gilteritinib shows encouraging benefits in patients with newly diagnosed FLT3-mutated AML who were ineligible for intensive chemotherapy.

Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, after reduced recurrence risk in lidERA trial.

Updated ASTCT infectious disease guidelines reshape approaches to prophylaxis, treatment thresholds, and drug-drug interactions in opportunistic infections.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

In this interview, Chris Elder, PharmD, BCOP, discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

The new indication is for patients aged 12 and older with unresectable or metastatic SS who received prior chemotherapy and are positive for various genetic subtypes.

In this interview, Sonia Amin Thomas, PharmD, BCOP, AFMCP, INHC, discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

This OPC interview discusses emerging personalized immunotherapy approaches in melanoma, evolving toxicity management strategies, and the future role of cancer vaccines in cutaneous oncology.

Kim Nguyen, PharmD, discusses findings from her OPC abstract on cardiovascular toxicities and drug-drug interactions associated with BTK inhibitors, highlighting strategies for individualized treatment selection and patient monitoring.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Pharmacy streamlines bispecific programs with tailored operations, scheduling, order sets, and reimbursement checkpoints.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This OPC interview discusses the growing importance of molecular testing, care coordination, and oral oncology therapies in optimizing outcomes for patients with gastrointestinal malignancies.

The growing importance of comprehensive biomarker testing, toxicity management, and the expanding role of targeted therapies in early-stage thoracic malignancies.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This OPC interview discusses emerging standards of care in genitourinary cancers, the growing role of molecular testing and minimal residual disease monitoring, and how oncology pharmacists can optimize treatment management.

This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.